Management of Phenytoin Level 24.5 µg/mL
Hold phenytoin immediately and monitor closely for signs of toxicity, as this level is above the therapeutic range (10-20 µg/mL) and places the patient at significant risk for dose-related adverse effects including ataxia, nystagmus, tremor, somnolence, and potentially life-threatening cardiac complications. 1, 2
Immediate Actions
1. Discontinue Phenytoin
- Stop all phenytoin administration immediately - the level of 24.5 µg/mL exceeds the therapeutic range and increases risk of toxicity 2
- Do not resume dosing until level falls into therapeutic range
2. Assess for Toxicity
Monitor for dose-related adverse effects that occur with supratherapeutic levels 1:
- Neurological: Ataxia, nystagmus, tremor, somnolence, cognitive impairment
- Cardiac: Dysrhythmias, hypotension, bradycardia, cardiac arrest (especially if given IV)
- Other: Purple glove syndrome (if IV administration), tissue necrosis
3. Clinical Monitoring
- Continuous cardiac monitoring if patient received recent IV phenytoin
- Serial neurological examinations
- Vital signs every 15-30 minutes initially
- Assess for seizure activity
Understanding the Pharmacokinetics
Critical pitfall: Phenytoin exhibits saturable (zero-order) kinetics at therapeutic levels, meaning small dose increases can cause disproportionate rises in serum concentration 2. At levels of 24.5 µg/mL, the elimination half-life is prolonged, and the drug will take longer to clear than expected.
The plasma half-life averages 22 hours (range 7-42 hours) but is significantly prolonged at supratherapeutic levels due to saturation of hepatic enzymes 2. This patient's level will decline slowly.
Subsequent Management
Repeat Level Timing
- Recheck phenytoin level in 24-48 hours given the prolonged half-life at toxic levels
- Continue holding phenytoin until level falls to 15-18 µg/mL range
- Steady-state requires 5-7 half-lives, so expect slow decline 2
When to Resume Therapy
Once level falls to 15-18 µg/mL:
- Resume at a reduced maintenance dose (typically reduce by 25-50% from previous dose)
- Recheck level in 5-7 days after dose adjustment 2
- Target therapeutic range: 10-20 µg/mL 2
Consider Alternative Agents
Given phenytoin's complex pharmacokinetics, narrow therapeutic index, and this patient's demonstrated difficulty maintaining therapeutic levels, strongly consider transitioning to an alternative antiepileptic drug such as levetiracetam or valproate, which have:
- More predictable pharmacokinetics
- Wider therapeutic windows
- Fewer drug interactions
- Better safety profiles 3, 4
Special Considerations
Protein Binding
- Phenytoin is 90-95% protein bound 5
- If patient has hypoalbuminemia, renal failure, or is critically ill, consider measuring free phenytoin level as total level may overestimate toxicity risk 6
- Free phenytoin therapeutic range: 1-2 µg/mL
Drug Interactions
Review all medications for:
- Enzyme inhibitors that increase phenytoin levels (e.g., valproate, certain antibiotics, antifungals)
- Drugs displaced from protein binding (e.g., valproate, aspirin)
- Adjust or discontinue offending agents if identified 7, 5
Seizure Risk During Dose Adjustment
- Patient remains at risk for breakthrough seizures as level declines
- Have rescue benzodiazepine readily available
- Educate patient/family about seizure precautions
- Consider bridging with alternative agent if high seizure risk
Documentation
Document:
- Time phenytoin was held
- Clinical assessment for toxicity
- Plan for repeat level and dose adjustment
- Patient/family education provided
- Follow-up arrangements
The key principle: Treat the patient, not just the number 8. While 24.5 µg/mL is supratherapeutic, some patients tolerate higher levels without toxicity. However, the risk-benefit ratio strongly favors holding the drug and allowing levels to decline given the potential for serious adverse effects, particularly cardiac complications 1.